We observed comparable inhibition of the EGFR signaling network by WSD-0922 and erlotinib in flank tumor models, where BBB considerations are not pertinent (Figure 2D, Supplementary Figure 3), and in intracranial tumors (Figure 4). Here, EGFR is linked to neoplasm.